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Abstract. The predicted reciprocal creatinine at age 
10 years (PRC10), a parameter of renal function based upon 
the linear relationship between reciprocal serum creatinine 
and age, incorporates age, serum creatinine, and rate of 
renal deterioration into a single term. PRCt0 measurements 
were employed to assess renal function in children with 
nephl-opathic cystinosis treated with oral cysteamine, a 
cystine-depleting agent. In 71 children receiving oral cys- 
t~amine for at least 1 year, PRC~0 decreased linearly with 
initial serum creatinine concentration. This indicated that, 
although established renal damage in cystinosis was irre- 
versible, early intervention with cysteamine therapy could 
favorably alter the rate of glomerular deterioration. In other 
analyses, mean PRC10 was shown to increase with duration 
of cysteamine therapy and extent of leukocyte cystine 
depletion. The predicted reciprocal creatinine value at a 
certain age can be useful in analyzing the effects of thera- 
peutic intervention in a disease with a relatively uniform 
rate of renal deterioration. 
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Introduction 
Creatinine clearance is currently the most widely em- 
ployed measure of glomerular filtration rate (GFR) in chil- 
dren with progressive renal disease. One particularly useful 
application of creatinine clearance measurements is to 
compare values before and after a specific therapy. How- 
ever, creatinine clearance may not reflect GFR under all 
conditions [1], and other estimates of GFR require either 
complete urine collections, or injection of compounds 
which are filtered but not reabsorbed or secreted. These 
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procedures may be difficult to perform uniformly and re- 
producibly when many centers are involved in a study 
protocol. As an alternative, formulas involving height can 
be employed [2], but height itself may change, inde- 
pendently of renal function, due to the therapy under inves-  
tigation. 
Because of these reservations, we introduced a renal 
function parameter that incorporates age, initial serum 
creatinine, and rate of progression of renal disease into a 
single term, i.e., the predicted reciprocal serum creatinine 
at a certain age. The use of this determination is based upon 
the linear relationship between reciprocal serum creatinine 
and age, which characterizes progressive renal disease of 
adults [3] and children [4-6] .  In children, the age for 
which the reciprocal serum creatinine is predicted can be 
the age at which renal failure is generally reached for the 
particular disease involved. 
That age would be 10 years for nephropathic cystinosis 
[7]. This lysosomal storage disease is a rare autosomal 
recessive disorder resulting from defective transport of the 
disulfide amino acid cystine across the lysosomal mem- 
brane [8-11] .  Intracellular cystine accumulates to 50- to 
100-fold normal levels in leukocytes and cultured fibro- 
blasts, and to 1000-fold normal levels in other tissues [12]. 
This apparently causes the clinical and pathological find- 
ings of the disease [12, 13], which include renal Fanconi 
syndrome in infancy, growth retardation, photophobia, and 
late findings [14] such as hypothyroidism [15], pancreatic 
insufficiency [16, 17], comeat erosions and decreased vi- 
sual acuity [18], and myopathy [19]. The most characteris- 
tic manifestation of nephropathic cystinosis is progressive 
glomerular deterioration requiring dialysis or renal trans- 
plantation by approximately 10 years of age [12, 13]. 
The specific therapy for cystinosis is cysteamine ([3- 
mercaptoethylamine), a free thiol capable of depleting over 
90% of the cystine in cystinotic leukocytes in vitro or in 
vivo [20]. Cysteamine accomplishes this by reacting with 
intralysosomal cystine to form cysteine, which rapidly 
leaves cystinotic lysosomes [8], and cysteine-cysteamine 
mixed disulfide. This compound leaves cystinotic lyso- 
somes much faster than does cystine itself [21], and does so 
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via  a ly sosomal  carrier  sys tem for lysine which  is intact  in 
cyst inot ic  lysosomes  [22]. 
W e  demonst ra ted  the uti l i ty of  the pred ic ted  rec iprocal  
creat inine at age 10 (PRC10) by  apply ing  it to patients with 
nephropathic  cyst inosis  t reated with cys teamine  for 0 - 7 3  
months.  A nat ional  col labora t ive  s tudy based  on creat inine 
clearance determinat ions  concluded  that chronic cys-  
teamine  therapy he lped  preserve  renal  funct ion in cyst ino-  
sis [7]. Analys i s  by  PRCI0 not  only  conf i rmed this f inding 
(ver i fying the val id i ty  of  the PRC10 determinat ion) ,  but 
also contr ibuted impor tant  new informat ion concerning 
cys teamine  therapy in cyst inosis  which could  not  be 
g leaned f rom creat inine c learance measurements  alone. 
Methods 
Data. The data were taken from the national collaborative cysteamine 
study, in which 93 children with cystinosis were treated for up to 73 
months between 1978 and 1985 with cysteamine hydrochloride (Sigma 
Chemical, Human Use Division, St. Louis, Mo., USA) at an average dose 
of 51.3 _+ 7.2 mg/kg per day (expressed as cysteamine free base), given 
every 6 h [7]. The mean leukocyte cystine level prior to treatment was 
9.3 nmol l/2 cystine/mg protein (normal, <0.2), and cysteamine reduced 
this, on average, by 82%. Fifty-five children with cystiuosis treated 
between 1976 and 1978 [23] with either ascorbic acid (27 patients given 
200 mg/kg per day) or placebo (28 patients), but not with cysteamine, 
served as historical control subjects. A concurrent control group would 
have been superior, partly because supportive care may have improved 
between 1976 and 1985. However, it seemed inappropriate to withhold 
cystine-depleting therapy from a group of patients with a fatal disease 
whose natural history was well recognized. 
Data for the placebo and ascorbic acid subjects were pooled for 
analyses, since the two groups did not differ significantly from one 
another in baseline parameters, including initial creatinine (two-sided 
P >0.2), nor did they differ significantly upon follow-up. 
Patients were examined every 4 months at 1 of 53 medical centers, 
where blood chemistry and parameters of growth and renal function were 
measured. GFR (expressed in ml/min per 1.73 m 2 body surface area) was 
estimated by the formula: 0.55 • height (cm)/serum creatinine (mg/dl) 
[2]. This equation gave values that correlated well with creatinine clear- 
ance values determined through 24-h urine collections in 22 children 
with cystinosis (r = 0.88) [7] and 77 children without cystinosis 
(r = 0.905) [21. 
StatisticaIprocedures. The PRCI0 for each subject was calculated by first 
estimating, by linear regression techniques, the best-fitting straight line 
that related the subject's reciprocal serum creatinine measurements to the 
age when each measurement was made; the resulting equation was then 
evaluated at age 10 to obtain the prediction. In testing the linearity of 
relationships, the dependent variable was grouped into categories so that 
a lack of fit statistic could be estimated and tested through analysis of 
variance [24]; in addition, a runs test [25] and the sign test [26] were 
applied to residuals to assess their randomness as an indicator of good- 
ness of fit. The observed differences in PRC:0 (or creatinine clearance) 
between treatment groups could be attributed to pretreatment differences 
in other factors (i. e., covariates), such as initial creatinine and age at 
entry into the study. The effects of these factors were removed by 
analysis of covariance [27]. In this procedure the linear relationship 
between the covariate and PRC~0 was used to estimate the effect of the 
covariate and to subtract the effect from the observed PRC10, so that the 
remaining differences were due only to the treatment effect. 
Results 
Reciprocal serum creatinine as a function of  age 
in cystinosis 
The rec iprocal  of  serum creat inine has been shown to 
decrease  approx imate ly  l inear ly  with age in individuals  
with progress ive  renal  d isease  [ 3 - 6 ] .  This re la t ionship was 
demons t ra ted  for f ive cyst inosis  pat ients  in two o f  these 
studies [5, 6], as wel l  as for f ive other cyst inosis  chi ldren in 
a separate repor t  [28]. 
W e  examined  the l inear i ty  of  reciprocal  serum creati-  
nine with age in our own patients in two ways.  First ,  the 
chi ldren with p rogress ive ly  increasing serum creat inine 
values were  invest igated longitudinal ly.  Thir ty pat ients  
(14 cysteamine- t reated,  16 controls) ,  fo l lowed for  an aver- 
age of  29 months ,  had indiv idual  correlat ion coeff icients  
for rec iprocal  creat inine versus age ranging f rom 0.73 to 
1.00 (mean _+ SD, 0.93 + 0.09). This compares  wel l  with 
the mean  correla t ion coeff ic ient  of  0.93 prev ious ly  re- 
por ted  for 29 patients wi th  a variety of  renal  d isorders  and 
progress ive ly  increas ing serum creat inine values  [6]. 
Examples  of  our pat ients '  individual  plots are g iven in 
Fig.  1. 
Second,  the rec iprocal  creat inine versus age relat ion- 
ship was s tudied cross-sect ional ly  (Fig. 2). In this analysis,  
each of  141 subjects  with nephropath ic  cyst inosis  was rep- 
resented by a s ingle reciprocal  serum creat inine value  pr ior  
to the ini t iat ion of  any cys t ine-deple t ing  therapy.  Despi te  
the he terogeneous  severi ty of  the cyst inosis  in these sub- 
jects ,  the data approx imate ly  fit a straight l ine correspond-  
ing to the equation y = - 0 . 0 1 3 x  + 1.72, where  y is 
rec iprocal  creat inine in (mg/dl ) - I  and x is age in months 
(Fig. 2). This  c losely  resembled  the pretreatment  l ine ob- 
ta ined by  Yudkof f  et al. [28]. In that study, age was expres-  
sed in terms of  months  and a negat ive  sign was omit ted  
f rom the publ i shed  s lope o f  the line, descr ibed  by 
y = 0 . 0 1 6 x  + 1.78. A n  examinat ion  of  the lineaxity as- 
sumpt ion  for  our analysis  ver i f ied that a s traight  l ine appro-  
pr ia te ly  descr ibed  the data. 
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Fig. 1. Longitudinal analysis of reciprocal serum creatinine as a ftmction 
of age. Reciprocal serum creatinine values in (mg/dl) -] were plotted 
against age for three children with cystinosis. B.M. (A) and S.H. (9 
took suboptimal doses of oral cystearnine starting at 5 years of age. D.W. 
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Fig. 2. Cross-sectional analysis of reciprocal serum creatinine as a func- 
tion of  age. Baseline serum creatinine (mg/dl) was determined for each of  
141 children with cystinosis referred for possible entry into study as 
either cysteamine-treated subjects or controls. Twelve observations are 
superimposed on others. The line was determined by the least-squares 
method and followed the equation y = -0.161 x + 1.72. The correlation 
coefficient was 0.62. The slope, whose standard error was 0.018, differed 
significantly from zero (P = 0.0001). Expressing age in terms of months, 
the equation is y = -0.013 x + 1.72 
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Fig. 3. Reciprocal serum creafinine as a function of  age for a cystinosis 
patient before and after initiation of cysteamine therapy. The a r r o w  
signifies initiation of effective cystine-depleting therapy. Both lines were 
constructed by the least-squares method and include the 38-month 
values. Cysteamine therapy changed the PRCI0 from -0 .99  to +0.21 
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Determination of PRClo 
By analyzing each individual's data longitudinally, a pro- 
jected value for reciprocal creatinine at age 10 could be 
determined. This indicated the rate at which renal damage 
was proceeding; a value above 1 meant that the predicted 
serum creatinine at age 10 would be less than 1. A value 
less than 0.1 (or negative) meant that kidney failure (serum 
creatinine >10 mg/dl) would occur before age 10. 
The influence of cysteamine therapy upon PRC10 is 
illustrated in an exceptional patient who did not receive 
significant amounts of cysteamine until 38 months of age 
(Fig. 3). This girl's creatinine clearance had fallen from 
28.4 to 17.3 ml/min per 1.73 ma between 16 and 38 months 
of age. It fell further to 15.3 ml/min per 1.73 m 2 by 84 
months of age. Using PRC10 analysis, her value was -0.99 
prior to the initiation of substantial cystine depletion, and 
she was predicted to attain a serum creatinine of 10 mg/dl 
at age 54 months. After the start of robust cysteamine 
therapy, her PRC10 changed to +0.21, with the prediction 
that a serum creatinine of 10 mg/dl would be reached at 
172 months of age. 
PRC10 determinations were performed on restricted 
groups of the cysteamine-treated and control populations. 
Children were required to be on the study for at least 12 
months, to have contributed data to the study on at least 
three different occasions, and to have had an initial serum 
creatinine of less than or equal to 2.0 mg/dl. These restric- 
tions served to remove very short-term compliers and chil- 
dren already approaching terminal renal failure at the time 
they began treatment. The restricted cysteamine group con- 
tained 71 children (76% of the total population who re- 
ceived cysteamine), and the restricted control group con- 
tained 39 children (71% of the total control population). 
During the course of investigation, 11 of the 71 cys- 
teamine-treated (15%) and 8 of the 39 control children 
(21%) withdrew from the study due to non-compliance or 
renal failure; all data analyses were performed on the entire 
110 children in the restricted study groups, regardless of 
whether they subsequently withdrew from the study. 
Table 1. Renal function in restricted treatment groups 
Cysteamine (n = 71) Control (n = 39) P 
x • SEM x • SEM 
Initial creadnine (mg/dl) 0.97 • 0.05 1.19 • 0.06 0.0090 
Initial age (years) 3.3 • 0.2 4.4 • 0.3 0.0086 
Final age (years) 6.7 •  6.0 • 0.3 0.1122 
Time on study (years) 3.3 • 0.2 1.6 • 0.1 0.0001 
Final creatinine clearance 
(ml/min per 1.73 m 2) 
-unadjus ted  43.8 •  27.8 •  0.0001 
-ad jus ted  a 41.8 • 1.7 31.9 •  0.0048 
PRC~0 (mg/dl)-~ 
- unadjusted 0.66 • 0.08 0.19 • 0.08 0.0002 
- adjusted b 0.62 • 0.07 0.33 • 0.10 0.0202 
For final age, initial age, and initial creatinine by analysis of covariance. (This also adjusts for time on study) 
b For initial age and creatinine 
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Occasionally, the regression of reciprocal creatinine 
versus age gave a positive slope, e.g., when only three 
creatinine values were available or an infant's initial creat- 
• was 0.6 mg/dl and fell to 0.4 mg/dl a year later. This 
type of fluctuation was presumed to reflect laboratory 
variation or lack of progression of renal disease, and a 
value of zero was assigned to the slope. This occurred 18 of 
71 and 6 of 39 times for the cysteamine and control groups, 
respectively. 
Applications of the PRClo 
Mean PRC10 values were determined for the restricted 
cysteamine and control groups, and compared with the 
mean final creatinine clearance values (Table 1). Both par- 
ameters demonstrated the maintenance of renal glomerutar 
function by chronic cysteamine therapy, even after statisti- 
cal adjustments were made for differences in initial age and 
serum creatinine between the two study groups. The PRC10 
data would predict mean serum creatinine levels of 1.51 
and 5.26 mg/dl for the cysteamine and control groups, 
respectively, at age 10 years. 
Table 2. Study groups stratified by time on cysteamine 
Duration of cysteamine therapy (months) 
0 a 12-24 25-48 49-73 
20 20 23 28 
Mean time on study (months) 19.9 18.8 35.3 57.3 
Initial age (years) 4.35 • 0.43 b 3.75 • 0.53 2.94 • 0.43 3.40 • 0.32 
Initial creatinine (mg/dl) 1.17 • 0.07 1.12 • 0.11 0.93 • 0.10 0.90 • 0.06 
Creatinine clearance 
(ml/min per 1.73 m 2) 
-initial 43.3 •  50.4 •  57.62++5.1 55.6 _+3.3 
-f inal  37.4 •  51.8 • 58.8 25.1 56.9 • 
-(final-initial) -5.9 _+3.0 1.4 •  1.2 •  1.4 •  
PRC10 
- unadjusted 0.22 • 0.12 0.49 • 0.20 0.60 _+ 0.13 0.84 • 0.09 
- adjusted for 0.40+0.15 0.55• 0.54_+0.12 0.79• 
initial age 
and creatinine 
a Placebo control group 
b SEM 
Table 3. Stratification according to leukocyte cystine levels 
Leukocyte cyst• depletion groups a 
1 2 3 4 
19 18 16 18 
Initial age (years) 3.27 + 0.52 b 2.98 • 0.37 2.90 • 0.55 4.20 _ 0.43 
Initial creatiniue (rag/all) 0.87 • 0.07 0.91 • 0.09 0.80 • 0.10 1.29 • 0.10 
Creatinine clearance 
(ml/min per 1.73 m 2) 
-initial 56.6 •  57.8 •  62.42+• 43.0 • 
- final 64.6 •  59.2 +6.4 63.0 • 7.0 37.9 + 6.9 
-(final-initial) 8.0 +5.8 1.4 _+4.2 0.5 • -5.0 •  
p* 0.374 0.450 0.066 
PRC~0 0.96 • 0.11 0.65 • 0.12 0.68 + 0.20 0.35 • 0.18 
p* 0.064 0.203 0.006 
a Groups 1-3:Twoormoreleukocytecystinelevelsobtainedperyear 
Group 1: Median level <1 nmol I/2 cystine/mg protein 
Group 2: Median level between 1 and 2 nmol 1/2 cystine/mg protein 
Group 3: Median level over 2 nmol 1/2 cystine/mg protein 
Group 4: Fewer than two levels obtained per year or could not tolerate 
full recommended dose of cystearnine 
b SEM 
* Two sidedP value compared with group 1, using Student's t-test 
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Fig. 4. Predicted reciprocal creatinine at age 10 (PRC10) as a function of 
initial serum creatinine in children receiving cysteamine. Calculation of 
the PRC10 is described in the text. Points in parentheses have negative 
values, reflecting the fact that renal failure was predicted to occur well 
before age 10. The line, whose equation is y = 0.64 x + 1.29, represents 
the best least-squares fit of the data. Testing of  residuals verified the 
linearity. The correlation coefficient was 0.41. The slope, whose standard 
error was 0.172, differed significantly from zero (P = 0.0004) 
The utility of the PRC10 value became apparent when 
renal function was assessed as a function of specific 
parameters in the restricted subject populations. For exam- 
ple, the PRC]0 was plotted against initial serum creatinine 
in the control group, and no trend was apparent (data not 
shown). This was expected since, without salutary inter- 
vention, the PRCm will not be altered by merely "follow- 
ing" the patient; it will be the same for a patient initially 
examined when his/her serum creatinine is 2.0 mg/dl as for 
one assessed when his/her serum creatinine is 0.6 mg/dl. 
The renal damage will progress inexorably, as predicted.  
In contrast, if intervention is beneficial, the PRC10 should 
increase with therapy, and should be greater in patients 
treated early (e. g., serum creatinine 0.6 mg/dl) than in 
those already having substantial renal damage (serum 
creatinine 2.0 mg/dl). This is exactly what was observed 
for the cysteamine-treated group; the PRC10 decreased 
when plotted against initial serum creatinine concentration 
(Fig. 4). It is apparent that renal damage already present is 
irreversible, but cysteamine therapy can favorably alter the 
PRClo, i. e., preserve remaining renal function. 
Subgroups of children stratified according to duration 
of cysteamine therapy were also analyzed (Table 2). 
Differences between final and initial creatinine clearance 
determinations did not reveal any benefit attributable to 
progressively longer durations of cysteamine therapy. 
PRCto determinations, however, showed a clear benefit 
attributable to increasing duration of cysteamine treatment. 
Although only the zero time and 49-73 months treatment 
groups differed significantly from one another in adjusted 
PRC10 (P = 0.042), there was an obvious trend of increas- 
ing PRC10 with time on study. In fact, when PRC10 was 
plotted against months on study for each of the 71 cys- 
teamine-treated children (data not shown), the slope was 
positive (0,0t7) and significantly different from zero 
(P = 0.009), even after effects of initial age and initial 
Table 4. PRCm for cysteamine and control subgroups ~ 
Patients over 3 years of age Cysteamine Controls P* 
n 31 30 
Initial age (years) 5.28 _+ 0.25 5.05 + 0.24 0.503 
Initial creatinine (mg/dl) 1.22 + 0.07 1.20_+ 0.07 0.788 
PRClo 0.50-+_ 0.08 0.21 • 0.09 0.015 
All values are means + SEM 
* Two-s idedP value using Student's t-test 
creatinine were adjusted for by analysis of covariance. For 
the 39 children in the control group, time on study had no 
effect on PRC10 (data not shown). 
The PRC10 determination was also applied to groups 
stratified according to the extent of leukocyte cystine 
depletion (Table 3). Reduction of the leukocyte cystine 
level to less than 1 nmol 1/2 cystine/mg cell protein is con- 
sidered excellent depletion, and was associated with a high 
PRC10 (n = 19, PRCt0=0 .96+0 .11  SEM, adjusted 
PRC10 = 0.91). This group differed from the group of least- 
compliant patients, who contributed fewer than two cystine 
levels per year or had leukocyte cystine levels over 3 nmol 
l/2 cystine/mg protein because they could not tolerate the 
recommended dose of cysteamine (n - 18, PRC10 = 
0.35+0.18, adjusted PRC10 = 0.53). Changes in creat- 
inine clearance values before and after therapy did not 
differ significantly among the various compliance groups 
(Table 3). 
Finally, we addressed the issue of whether initial age or 
initial serum creatinine at the start of cysteamine therapy 
determined ultimate renal outcome. Cysteamine-treated 
and control subjects were grouped by initial age over 
3 years and the mean PRC10 value determined (Table 4). 
Cysteamine therapy proved beneficial even in this group of 
children over age 3, despite their elevated mean initial 
serum creatinine level (1.2 mg/dl), indicating that even 
relatively late intervention can be helpful. 
Discussion 
Two parameters for assessing renal function in children, 
the creatinine clearance rate and the PRC10, have their own 
advantages and disadvantages. Creatinine clearance re- 
quires urine collection or else relies upon height measure- 
ments, and it varies with age. The PRCt0 requires only 
serum creatinine determinations, and represents a single 
value which incorporates the parameters of initial age, 
initial serum creatinine and rate of renal deterioration. 
Moreover, it uses all of the available data points rather than 
just the final one. In a disease with a constant rate of renal 
deterioration, the PRC10 does not change with age unless 
some intervention (e. g., therapy) alters that rate. Because a 
single number denotes each individual's PRCt0, this term 
lends itself to mathematical manipulations much more 
readily than an age-varying rate such as creatinine clear- 
ance. On the other hand, there is no "initial" and "final" 
PRClo, so that only rarely (e. g., Fig. 3) can a patient be 
used as his or her own control. In addition, the PRCt0 
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requires follow-up of long enough duration to determine 
the rate of renal deterioration. Our choice of at least 
12 months of follow-up was somewhat arbitrary; it may 
not be optimal for cystinosis, nor sufficient for other renal 
diseases. 
A final caveat is that, although there is ample evidence 
that the relationship of reciprocal serum creatinine versus 
age is just as linear in cystinosis as in other renal diseases, 
this relationship manifests itself only with progressive re- 
nal deterioration. Patients with constant, low creatinine 
values may make the slope portion of the PRC10 determi- 
nation appear precarious. However, the PRC10 also relies 
upon the actual value of the serum creatinine which, if 
relatively constant, has been strengthened by being mea- 
sured repeatedly over the course of follow-up. This offsets 
the fact that a slope near zero results in a poor correlation 
coefficient for the reciprocal creatinine versus age curve. 
One measure of the overall validity of the PRC10 calcula- 
tion is that, for the entire study group of cystinosis patients, 
it gave results which coincided with the creatinine clear- 
ance results (Table 1). 
In choosing the PRC10 as a parameter to follow in 
children with cystinosis, several alternatives were dis- 
carded. The age at which reciprocal creatinine was pre- 
dicted to be 0.1 (mg/dl) -1 could not be used, because this 
value would be infinity in patients whose reciprocal creat- 
inine versus age curve had a positive or zero slope. Com- 
paring the slopes themselves was not very useful because 
slope values do not contain enough information, i. e., there 
is no consideration of initial age or initial creatinine value. 
Hence, much of the information inherent in the PRC10 
would be lacking, and statistical significance would be 
reduced when comparing data for subgroups of treated 
patients. Finally, predicting the serum creatinine itself at 
age 10 for each individual was not helpful because the 
high values in any group of patients disproportionately 
weighted the mean for that group. 
It also became apparent that the PRC10 could be ap- 
plied to large groups of patients whose rates of renal dete- 
rioration were rapid and uniform. These qualifications 
were met by the group of patients investigated to determine 
whether chronic oral cysteamine therapy helped preserve 
renal function in cystinosis [7]. Data from a control group 
were available [23], patients were followed for a consider- 
able period of time with serum creatinine measurements, 
and the disease itself had a fairly uniform natural history of 
renal deterioration. In fact, the data of Fig. 2, which predict 
that a serum creatinine of 10 mg/dl will be reached at a 
mean age of 10.1 years, confirmed previous reports of the 
age at renal failure in cystinosis. In a survey of 205 
European children with cystinosis, the median age of renal 
failure was 9.2 years [29]. 
The decreasing relationship between PRCI0 and initial 
serum creatinine among cysteamine-treated children 
(Fig. 4) indicates that the greater the renal damage at the 
start of cysteamine therapy, the less benefit would accrue 
from subsequent cystine depletion. That is, the renal dam- 
age of cystinosis appears irreversible, and cysteamine's 
effect was not curative. However, cysteamine does alter the 
course of renal disease in cystinosis to an extent inversely 
related to the degree of existing renal damage. 
Conclusions such as these were difficult to make using 
creatinine clearance measurements. For example, if final 
creatinine clearance rather than PRC 10 were plotted against 
initial serum creatinine (as for Fig. 4), the results would be 
inconclusive because the final creatinine clearance de- 
pends so heavily upon the final age, which varied exten- 
sively among the subjects. Hence, the random variation in 
the data would obscure the trend apparent in Fig. 4 using 
the PRC10 (which does not vary with age). 
Other conclusions drawn from PRC~0 analyses in- 
cluded the findings that the extent of preservation of renal 
function increased with duration of cysteamine therapy 
(Table 2) and with extent of leukocyte cystine depletion 
(Table 3). These conclusions were difficult or impossible 
to derive from creatinine clearance measurements before 
and after treatment (Tables 2, 3). The PRC10 findings re- 
present important evidence confirming the efficacy of cys- 
teamine therapy in nephropathic cystinosis, and indicate 
that more and longer cystine depletion is preferable in 
treating this disease. 
Use of predicted reciprocal creatinine values may be 
helpful in assessing therapies for other renal diseases 
besides cystinosis. Extensive longitudinal data would be 
needed on treated as well as untreated patients, and the 
renal disease must be shown to be uniformly progressive 
(see Fig. 1) and reasonably homogeneous with respect to 
age at renal failure. The appropriate calculation to make 
would be the predicted reciprocal creatinine for the average 
age at which renal failure is expected. 
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